CABASER

This brand name is authorized in Australia, Finland, Ireland, Japan, Turkey, United Kingdom

Active ingredients

The drug CABASER contains one active pharmaceutical ingredient (API):

1 Cabergoline UNII LL60K9J05T - CABERGOLINE

Cabergoline is a dopaminergic ergoline derivative endowed with a potent and long-lasting PRL-lowering activity. Read about Cabergoline

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CABASER Tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N04BC06	Cabergoline	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BC Dopamine agonists
Discover more medicines within N04BC06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 8393R, 8394T
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 007149
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 20903, 20906
Country: IE	Health Products Regulatory Authority	Identifier(s): 15902
Country: JP	医薬品医療機器総合機構	Identifier(s): 1169011F1028, 1169011F2024
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681308011091, 8681308011107